NO943645L - Enantiomerisk 1-fenyl-2-(2-pyridinyl)etylamin for behandling av neurodegenerative forstyrrelser - Google Patents

Enantiomerisk 1-fenyl-2-(2-pyridinyl)etylamin for behandling av neurodegenerative forstyrrelser

Info

Publication number
NO943645L
NO943645L NO943645A NO943645A NO943645L NO 943645 L NO943645 L NO 943645L NO 943645 A NO943645 A NO 943645A NO 943645 A NO943645 A NO 943645A NO 943645 L NO943645 L NO 943645L
Authority
NO
Norway
Prior art keywords
phenyl
treatment
neurodegenerative disorders
enantiomeric
ethylamine
Prior art date
Application number
NO943645A
Other languages
English (en)
Other versions
NO943645D0 (no
NO302170B1 (no
Inventor
Ronald Conrad Griffith
Robert John Murray
Michael Balestra
Original Assignee
Fisons Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929207339A external-priority patent/GB9207339D0/en
Priority claimed from GB929208290A external-priority patent/GB9208290D0/en
Application filed by Fisons Corp filed Critical Fisons Corp
Publication of NO943645D0 publication Critical patent/NO943645D0/no
Publication of NO943645L publication Critical patent/NO943645L/no
Publication of NO302170B1 publication Critical patent/NO302170B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
NO943645A 1992-04-03 1994-09-30 Enantiomerisk 1-fenyl-2-(2-pyridinyl)etylamin, farmasöytisk formulering og anvendelse derav NO302170B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929207339A GB9207339D0 (en) 1992-04-03 1992-04-03 Pharmaceutical compound
GB929208290A GB9208290D0 (en) 1992-04-15 1992-04-15 Pharmaceutical compound having neuroprotective properties
PCT/GB1993/000689 WO1993020052A1 (en) 1992-04-03 1993-04-01 Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders

Publications (3)

Publication Number Publication Date
NO943645D0 NO943645D0 (no) 1994-09-30
NO943645L true NO943645L (no) 1994-11-16
NO302170B1 NO302170B1 (no) 1998-02-02

Family

ID=26300643

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943645A NO302170B1 (no) 1992-04-03 1994-09-30 Enantiomerisk 1-fenyl-2-(2-pyridinyl)etylamin, farmasöytisk formulering og anvendelse derav

Country Status (28)

Country Link
EP (1) EP0633879B1 (no)
JP (2) JP3120810B2 (no)
KR (1) KR100259567B1 (no)
CN (1) CN1044367C (no)
AT (1) ATE163925T1 (no)
AU (2) AU3897693A (no)
CA (1) CA2133427C (no)
CZ (1) CZ288519B6 (no)
DE (1) DE69317411T2 (no)
DK (1) DK0633879T3 (no)
DZ (1) DZ1677A1 (no)
ES (1) ES2115055T3 (no)
FI (1) FI105025B (no)
HU (1) HU211529A9 (no)
IL (1) IL105276A (no)
MA (1) MA22866A1 (no)
MX (1) MX9301935A (no)
MY (1) MY110149A (no)
NO (1) NO302170B1 (no)
NZ (1) NZ251384A (no)
PL (1) PL180014B1 (no)
RU (1) RU2128650C1 (no)
SG (1) SG47948A1 (no)
SK (1) SK281258B6 (no)
TW (1) TW282455B (no)
UA (1) UA29437C2 (no)
WO (1) WO1993020052A1 (no)
ZA (1) ZA932415B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
SG52662A1 (en) * 1988-08-12 1998-09-28 Astra Ab Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
ZA942140B (en) * 1993-04-01 1994-10-03 Fisons Corp Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
HUP0202143A3 (en) * 1999-07-28 2003-12-29 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use
WO2007017652A2 (en) * 2005-08-10 2007-02-15 Astrazeneca Ab Arylakylamines for the treatment of cancer
BRPI0923476A2 (pt) * 2008-12-24 2016-01-19 Astrazeneca Ab composto, métodos para tratar depressão em um ser humano, e grande distúrbio depressivo, e, composição farmacêutica
JP2015501652A (ja) * 2011-12-14 2015-01-19 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Gabr−a2診断
SI3066091T1 (sl) 2013-11-05 2019-09-30 Astrazeneca Ab NMDA antagonist predzdravila
AU2021297823A1 (en) * 2020-06-23 2023-02-16 Biohaven Therapeutics Ltd. Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA889252B (en) * 1987-12-11 1990-08-29 Syntex Lab Neuroprotective compounds
SG52662A1 (en) * 1988-08-12 1998-09-28 Astra Ab Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties

Also Published As

Publication number Publication date
JP2000319259A (ja) 2000-11-21
HK1009331A1 (en) 1999-05-28
DZ1677A1 (fr) 2002-02-17
TW282455B (no) 1996-08-01
RU94042465A (ru) 1996-07-20
RU2128650C1 (ru) 1999-04-10
UA29437C2 (uk) 2000-11-15
ES2115055T3 (es) 1998-06-16
JP3120810B2 (ja) 2000-12-25
ZA932415B (en) 1993-10-22
CA2133427A1 (en) 1993-10-14
CZ240994A3 (en) 1995-12-13
MX9301935A (es) 1994-08-31
SK281258B6 (sk) 2001-01-18
AU7545696A (en) 1997-02-13
KR100259567B1 (ko) 2000-07-01
NO943645D0 (no) 1994-09-30
FI944546L (fi) 1994-09-30
WO1993020052A1 (en) 1993-10-14
CN1044367C (zh) 1999-07-28
NO302170B1 (no) 1998-02-02
DK0633879T3 (da) 1998-09-28
AU3897693A (en) 1993-11-08
HU211529A9 (en) 1995-11-28
SG47948A1 (en) 1998-04-17
DE69317411D1 (de) 1998-04-16
DE69317411T2 (de) 1998-07-30
CA2133427C (en) 2003-06-10
JPH07505385A (ja) 1995-06-15
IL105276A (en) 1997-06-10
EP0633879A1 (en) 1995-01-18
MY110149A (en) 1998-02-28
SK117794A3 (en) 1995-05-10
CZ288519B6 (cs) 2001-07-11
PL180014B1 (pl) 2000-11-30
FI944546A0 (fi) 1994-09-30
CN1081669A (zh) 1994-02-09
NZ251384A (en) 1996-10-28
FI105025B (fi) 2000-05-31
AU705419B2 (en) 1999-05-20
EP0633879B1 (en) 1998-03-11
ATE163925T1 (de) 1998-03-15
MA22866A1 (fr) 1993-12-31
IL105276A0 (en) 1993-08-18

Similar Documents

Publication Publication Date Title
FI954979A7 (fi) Kemoherkistävinä aineina käytettävät 10,11-metanodibentsosuberaanijohdannaiset
ITMI940326A0 (it) Derivati del 3,8-diazabiciclo[3.2.1.]lottano ad attivita' analgesica
CA2180535A1 (en) A method for treatment of psoriasis, by omeprazole or related compounds
NO972391L (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
NO943645D0 (no) Enantiomerisk 1-fenyl-2-(2-pyridinyl)etylamin for behandling av neurodegenerative forstyrrelser
NO912797L (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme karbostirilderivater.
FR2689508B1 (fr) Derives de l'imidazole, leur procede de preparation et leur application en therapeutique.
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
MA24130A1 (fr) PROCEDE DE PREPARATION D'ENANTIOMERES PURS D'ACIDES CYCLO-ALCANO-INDOLAZAINDOL ET PYRIMIDO-(1,2a) INDOL - CARBOCYCLIQUES ET LEURS DERIVES
NO972449D0 (no) Substituerte 2-arylkarbonyloksymetyl-1,2,5-tiadiazolidin-3-on 1,1 dioksidderivater og preparater og fremgangsmåte for anvendelse derav
CA2135709A1 (en) Melatonin derivatives for use in treating sleep disorders
NO953989D0 (no) Nye polysykliske systemer og derivater derav, som neurotransmitter frigivelses-forsökende midler som er anvendbare ved behandling av kognitive sykdommer
ITMI931019A0 (it) Derivati del cicloeptimmidazolo, metodo per la loro produzione e agenti terapeutici contenenti questi composti
NO924290L (no) Azabenzimidazoler for behandling av astma, artritt og lignende lidelser
AU8715491A (en) Melatonin derivative having therapeutic activity in dermatology
AU6581294A (en) Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
EP0636611A3 (en) Optically active 1,4-dihydropyridine derivatives and process for preparing the same.
AU647608B2 (en) Isoxazolylimidazole derivatives, process for their production and their use in pharmaceutical agents
IT1276321B1 (it) Derivati del carbossimetilidenecicloptimmidazolo procedimento di fabbricazione dei derivati e agenti terapeutici che contengono
RU95111888A (ru) Способ лечения периферических поражений лицевого нерва
IT1263076B (it) Uso orale e topico della n-acetil-5-metossitriptamina (melatonina) nella terapia della psoriasi volgare.
FI20040505A7 (fi) Menetelmä 1,3-dihydro-6-hydroksi-2H-indol-2-oni-johdannaisten valmistamiseksi
ITMI921770A1 (it) Composizioni farmaceutiche atte al trattamento dei disturbi della memoria.
ITMI931684A1 (it) Procedimento per la preparazione di derivati del 3, 4-diidrocarbostirile
ES1024890Y (es) Plantilla terapeutica perfeccionada.

Legal Events

Date Code Title Description
MK1K Patent expired